Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL849757 | 0.83 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL8001783 | 0.83 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL4453493 | 0.81 | SLC7A5 (0.36) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL4453499 | 0.81 | SLC7A5 (0.36) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL30443813 | 0.81 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL29022742 | 0.81 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL2381464 | 0.80 | CYP3A4 (0.34) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL31369905 | 0.79 | SLC7A5 (0.44) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL233540 | 0.78 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL29022786 | 0.78 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226608-A1 | IMMUNOTOXIN-ARMORED IMMUNE EFFECTOR CELLS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4096715-A1 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2022-12-07 | — | — | EP | claimed |
| US-20220305128-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-29 | — | — | US | claimed |
| EP-3986469-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2022-04-27 | — | — | EP | claimed |
| EP-3943939-A1 | MODIFICATION-DEPENDENT ACTIVITY ASSAYS | Takeda Pharmaceutical Company Limited (JP) | 2022-01-26 | — | — | EP | claimed |
| US-20210325368-A1 | METHODS DETERMINING AND TREATING CELLULAR RESISTANCE TO ADP-RIBOSYLATING TOXIN | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-10-21 | — | — | US | claimed |
| WO-2021155177-A1 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2021-08-05 | — | — | WO | claimed |
| WO-2020257730-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2020-12-24 | — | — | WO | claimed |
| US-20200348308-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | Encodia, Inc. (US) | 2020-11-05 | — | — | US | claimed |
| CN-105792942-B | Collector compositions and methods of making and using the same | 佐治亚-太平洋化工品有限公司 | 2019-04-16 | — | — | CN | claimed |
| US-7598031-B2 | Method for the detection of gene transcripts in blood and uses thereof | GENENEWS CORPORATION (CA) | 2009-10-06 | — | — | US | claimed |
| EP-2038415-A1 | DPH2 GENE DELETION MUTANT AND USES THEREOF | Caruso, Manuel (CA) | 2009-03-25 | — | — | EP | claimed |
| WO-2007143858-A1 | DPH2 GENE DELETION MUTANT AND USES THEREOF | CARUSO MANUEL (CA) | 2007-12-21 | — | — | WO | claimed |
| EP-1071334-A4 | A METHOD FOR EFFICIENT AND HIGHLY SELECTIVE CONTROL OF MICROORGANISMS | WHITEHEAD BIOMEDICAL INST (US) | 2004-03-10 | — | — | EP | claimed |
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | WILBURN MICHAEL D (US) | 2003-04-24 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-1071334-A1 | A METHOD FOR EFFICIENT AND HIGHLY SELECTIVE CONTROL OF MICROORGANISMS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2001-01-31 | — | — | EP | claimed |
| EP-0968282-A2 | VECTORS AND METHODS FOR EXPRESSION OF MUTANT PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-01-05 | — | — | EP | claimed |
| WO-1999053762-A1 | A METHOD FOR EFFICIENT AND HIGHLY SELECTIVE CONTROL OF MICROORGANISMS | MICROBIA, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| WO-1998039425-A2 | VECTORS AND METHODS FOR EXPRESSION OF MUTANT PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-09-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078231-A1 | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties | MAT1A, LPO, TPMT | SLC7A5 417/4885CYP3A4 2763/4885CYP1A2 2808/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | SLC7A5 993/4885CYP3A4 2879/4885CYP1A2 3715/4885 |
| US-20220305128-A1 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | RNMT, NSUN3, NSUN2 | SLC7A5 4056/4885CYP3A4 4876/4885CYP1A2 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.